UranwSBhattaraiNRClootsK, et al.Visceral leishmaniasis in the hills of western Nepal: a transmission assessment. PLoS One2024; 19: e0289578.
2.
World Health Organization. Regional Strategic Framework for accelerating and sustaining elimination of kala-azar in the Southeast Asia Region: 2022–2026.
3.
ShresthaMPandeyBDMaharjanJ, et al.Visceral leishmaniasis from a non-endemic Himalayan region of Nepal. Parasitol Res2018117: 2323–2326.
4.
GhimirePGGhimirePAdhikariJ, et al.A case report of visceral leishmaniasis and malaria co-infection with pancytopenia and splenomegaly - a diagnostic challenge. BMC Infect Dis2019; 19: 849.
5.
AronsonNHerwaldtBLLibmanM, et al.Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American society of tropical medicine and hygiene (ASTMH). Am J Trop Med Hyg2017; 96: 24–45.
6.
KosterKLLawsHJTroegerA, et al.Visceral leishmaniasis as a possible reason for pancytopenia. Front Pediatr2015; 3: 59.
7.
BuenoGCLKoerichATSBurgLB, et al.Visceral leishmaniasis mimicking systemic lupus erythematosus. Rev Soc Bras Med Trop2019; 52: e20180208.
8.
LiberopoulosEKeiAApostolouF, et al.Autoimmune manifestations in patients with visceral leishmaniasis. J Microbiol Immunol Infect2013; 46: 302–305.
9.
ZhangHYanRLiuY, et al.Progress in antileishmanial drugs: mechanisms, challenges, and prospects. PLoS Negl Trop Dis2025; 19: e0012735.
10.
Monge-MailloBLópez-VélezR. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clin Infect Dis2015; 60: 1398–1404.
